Patagonia is excited to announce that we have been awarded a grant of $1.5MM over three years through FDA's Orphan Products Clinical Trials Grants Program!  This non-dilutive funding will help support our clinical development of PAT-001, a proprietary topical formulation of isotretinoin in development for Congen...

Our team just returned from Nashville, TN, where FIRST hosted their biennial, national conference.  It was a fantastic opportunity to engage with a variety of stakeholders within the ichthyosis community, including KOLs, patients, and advocates.  

Our President, Zach Rome, sat on a panel alongside...

In a recent blog post from the FDA, Commissioner Scott Gottlieb acknowledges their role to help advance progress in biotechnology.  Their approach will focus on three key areas: "First, advancing and protecting public and animal health by promoting innovation through an efficient and predictable science- and ris...

Our team is excited to attend the 20th Biennial FIRST National Conference in Nashville, TN next month.  This will be our second time attending and something we continue to look forward to every couple years.  Not only is it a great opportunity to learn from a variety of stakeholders during the formal presentatio...

In March, the President signed the 2018 legislation that increased the budget for nearly all US science agencies, a $1.3 trillion spending deal.  This boosted funding for the National Institutes of Health (NIH) to a historic high of $37 billion, an increase of $3 billion over the 2017 levels. 

Additiona...

Patagonia is excited to announce the completion of our Phase 2a clinical study for PAT-001.  This proof-of-concept study was conducted at 5 sites throughout the United States and investigated the potential of PAT-001 in Congenital Ichthyosis. 

Ichthyosis is a family of genetic skin disorders characteriz...

Patagonia is excited to announce that we have completed enrollment in our Phase IIa study for congenital ichthyosis.  Ichthyosis is a family of genetic skin disorders characterized by dry, scaling skin that may be thickened or very thin. It affects people of all ages, races and gender. The disease usually presen...

John Maslowski recently published a very interesting article in Pharmaceutical Executive detailing various insights and information related to the developing of treatments for rare diseases.

To read the full article, please click on the following link: http://www.pharmexec.com/developing-drugs-rare-diseases-insig...

FDA Commissioner Gottlieb writes a post on the FDA's commitment to the Orphan Drug Act in the FDA Voice blog.  Please click the following link for the full post: 

https://blogs.fda.gov/fdavoice/index.php/2017/09/fda-is-advancing-the-goals-of-the-orphan-drug-act/